NCT05934942View on ClinicalTrials.gov

A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

February 8, 2024

Study Completion Date

February 8, 2024

Conditions
Healthy
Interventions
DRUG

Yasmin®

Ethinylestradiol (EE) and Drospirenone (DRSP)

DRUG

BI 1358894

BI 1358894

Trial Locations (1)

13627

CRS Clinical Research Services Berlin GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood | Biotech Hunter | Biotech Hunter